4.4 Article

Trends in Hip Fracture Incidence and in the Prescription of Antiosteoporosis Medications During the Same Time Period in Belgium (2000-2007)

Journal

ARTHRITIS CARE & RESEARCH
Volume 64, Issue 5, Pages 744-750

Publisher

WILEY
DOI: 10.1002/acr.21607

Keywords

-

Categories

Funding

  1. Servier
  2. European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis-MSD
  3. Novartis
  4. Negma
  5. Lilly
  6. Wyeth
  7. Amgen
  8. GlaxoSmithKline
  9. Roche
  10. Merckle
  11. Nycomed
  12. NPS
  13. Theramex
  14. UCB
  15. Merck Sharp Dohme
  16. Rottapharm
  17. IBSA
  18. Genevrier
  19. Teijin
  20. Teva
  21. Ebewee Pharma
  22. Zodiac
  23. Analis
  24. Novo Nordisk
  25. Bristol-Myers Squibb

Ask authors/readers for more resources

Objective. To examine the secular trend of hip fracture incidence in Belgium between 2000 and 2007 and the concomitant change in the prescriptions of antiosteoporosis medications. Methods. The incidence of hip fractures and the number of prescriptions were determined using national databases. A logistic regression including years and 5-year age range was performed to assess the secular trend of hip fracture incidence, and Pearson's correlation coefficient was calculated to examine the relationship between hip fracture incidence and the prescriptions of antiosteoporosis medications. Results. The annual number of hip fractures increased in Belgium from 13,512 in 2000 to 14,744 in 2007, with a more marked increased in men (20.4%) than in women (5.7%). The age-adjusted incidence of hip fractures was significantly decreased by 1.12% per year in women, but declined nonsignificantly by 0.34% per year in men. An increase in the prescriptions of antiosteoporosis medications in women was observed during the same time period. Conclusion. Despite an increase in the number of hip fractures in Belgium between 2000 and 2007, there was a significant decrease in age-adjusted incidence in women but not in men. Although our results suggest that the decrease may be related to the extent of antiosteoporosis medications, a causal relationship cannot be ascertained and many other factors may have contributed to the decrease in age-adjusted incidence.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available